Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.76 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | TSPO | P30536 | 1/20 | 0.72 |
| ▸ | BRD2 | P25440 | 8/20 | 0.70 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.70 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.70 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | JAK2 | O60674 | 1/20 | 0.69 |
| ▸ | BRD1 | O95696 | 1/20 | 0.69 |
| ▸ | CCL2 | P13500 | 1/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.69 |
| ▸ | EP300 | Q09472 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181973 | 1.00 | BRD4 (0.76) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL20466955 | 0.92 | BRD4 (0.74) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL21401829 | 0.92 | BRD4 (0.74) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL27363316 | 0.91 | BRD4 (0.64) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL16841486 | 0.91 | BRD4 (0.64) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL27363397 | 0.91 | BRD4 (0.64) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL881276 | 0.90 | BRD4 (0.77) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL17165536 | 0.90 | BRD4 (0.78) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL29666190 | 0.89 | BRD4 (0.74) | BRD4DNERADORA3TSPOBRD2 | |
| SCHEMBL27363445 | 0.89 | BRD4 (0.62) | BRD4DNERADORA3TSPOBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257128-A2 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| WO-2021087096-A1 | P53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| EP-3212654-B1 | BROMODOMAIN INHIBITORS | TENSHA THERAPEUTICS INC (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2019183600-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-2569434-B1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA AND RELATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2019-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | BRD4 2609/4885DNER 4464/4885ADORA3 2406/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | BRD4 205/4885DNER 3050/4885ADORA3 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.